Editing GSK plc (section)

==== Subsequent split ====
[[File:GSK logo 2014.svg|thumb|100px|Prior logo before 9 June 2022]]
The culmination of the Consumer Healthcare string of deals will result in GSK splitting into two separate companies, via a demerger and subsequent listing of the joint venture. This will create two publicly traded companies, one focusing on pharmaceuticals and research & development, the other on consumer healthcare. On 22 February 2022, GSK announced that the spin-off consumer healthcare company will be called [[Haleon]].<ref name=split/><ref>{{cite news |last=Freeman |first=Simon |date=22 February 2022 |title=Hello, Haleon: GlaxoSmithKline reveals name of £60bn consumer health spin-out |newspaper=Evening Standard |url=https://www.standard.co.uk/business/glaxosmithkline-gsk-names-spinoff-haleon-sensodyne-walmsley-elliott-b983928.html |url-status=live |access-date=23 February 2022 |archive-url=https://web.archive.org/web/20230405015033/https://www.standard.co.uk/business/glaxosmithkline-gsk-names-spinoff-haleon-sensodyne-walmsley-elliott-b983928.html |archive-date=5 April 2023}}</ref>

In January 2022, the company announced that they had received three unsolicited offers from [[Unilever]] to acquire the Consumer Healthcare business unit, with the final proposal valuing the business unit at £50 billion (£41.7 billion in cash, plus £8.3 billion in Unilever shares).<ref>{{Cite news |last1=Cavale |first1=Siddharth |last2=Burger |first2=Ludwig |last3=Dey |first3=Mrinmay |date=15 January 2022 |title=GSK rejects 50-billion-pound Unilever offer for consumer assets |newspaper=Reuters |url=https://www.reuters.com/business/retail-consumer/unilever-offers-50-bln-pounds-gsk-unit-report-2022-01-15/ |archive-url=https://web.archive.org/web/20220115110019/https://www.reuters.com/business/retail-consumer/unilever-offers-50-bln-pounds-gsk-unit-report-2022-01-15/ |archive-date=15 January 2022 |via=www.reuters.com}}</ref>

Subsequently, GSK declined all outside offers/attempts to acquire its consumer healthcare business and moved forward with its plan to complete the demerger from the main biopharmaceutical business.<ref>{{Cite web |url=https://www.ft.com/content/85f28cd9-ca18-4f2b-8346-c22efdfe1382 |archive-url=https://ghostarchive.org/archive/20221210/https://www.ft.com/content/85f28cd9-ca18-4f2b-8346-c22efdfe1382 |archive-date=10 December 2022 |url-access=subscription |title=Pfizer to exit GSK consumer health joint venture after London listing |newspaper=Financial Times |date=1 June 2022 |access-date=15 June 2022}}</ref>